NEW YORK, April 28, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

http://www.reportlinker.com/p0487247/Castration-Resistant-Prostate-Cancer-Clinical-Insights-from-a-US-Oncologists-Survey.html

Castration Resistant Prostate Cancer: Clinical Insights from a US Oncologists' Survey

Progressively unfolding patient situation, presented to 154 oncologists in a survey for their open-ended responses providing rich insight into their clinical decisions. Data includes specific treatment and testing choices, factors that influence their decisions, barriers to optimal treatment and confidence in treatment and management of patients.

This primary research provides the oncology prescribing information that you are missing, directly from high-prescribing US Oncologists on the treatment of patients with advanced prostate cancer.

Treatment decisions for advanced stages of cancer are difficult to track as information quickly changes along with the introduction of new information and products impacting oncologists' decisions. This series of reports will allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in advanced stages of cancer.

This report allows you to:

• Understand what occurs with actual patients

• Access the most up-to-date prescribing trends

• Gain actionable data for developing and improving your market strategies

• Pinpoint needs of your target audience

• Focus resources to maximize the effectiveness of your budget

• Understand where your product fits

• Understand where your competitor's product fits

• Design messages to advance brand performance

Table of Contents

Executive Summary:5

Chapter 1: Introduction7

Table 1. Treatment Options in Advanced Prostate Cancer8

Chapter 2: Respondent Demographics9

Table 2.1 Eligibility Criteria for Survey Participation9

Figure 2.1 Gender of Survey Respondents9

Figure 2.2 Years Since Medical School Graduation10

Figure 2.3 Practice Settings10

Figure 2.4 Practices in NCI Cancer Centers11

Figure 2.5 Geographic Settings11

Figure 2.6 Survey Respondents by States12

Figure 2.7 Number of Physicians in Practice Groups13

Figure 2.8 Minimal Acceptable Level of Evidence in Determining Treatment Regimen13

Chapter 3: Elderly patient treated for Gleason's 7 adenocarcinoma, increased PSA 18 months later14

Figure 3.1 Barriers to optimal treatment14

Figure 3.2 Confidence in treating to optimal outcome16

Figure 3.3 Treatment following rising PSA on leuprolide17

Figure 3.4 Treatment decision upon disease progression18

Figure 3.5 Factors that influenced treatment20

Table 3.1 Factors that influenced treatment by types of agents selected21

Figure 3.6 Other agents that would be appropriate to include in therapy22

Figure 3.7 Treatment upon rising PSA23

Figure 3.8 Treatment upon further disease progression24

Chapter 4. Patient with Gleason's 3+4 adenocarcinoma and multiple metastases to pelvis and spine develops castration-resistant disease.26

Figure 4.1 Treatment Choices26

Figure 4.2 Confidence in treating to optimal outcome27

Figure 4.3 Cycles of docetaxel that the patient should receive28

Figure 4.4 Option to Continue LHRH agonist29

Figure 4.5 Factors Associated with Continuing LHRH Agonist29

Figure 4.6 Next Therapy with Good Performance Status upon Progressing after Docetaxel31

Chapter 5: Summary32

Appendix A: Survey Instrument33

Companies mentioned

Novartis, Astra Zeneca, Merck, Ferring, Abbott Laboratories, TEVA, Eli Lilly, Genentech/Roche, Bristol-Myers Squibb, Pfizer, Sanofi-aventis, Centocor/Ortho Biotech, EMD Serono, Dendreon, Celegene, Watson, Amgen

To order this report:

:

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker